EP0797988A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anti-angiogenic compositions and methods of use
Assignee: University of British Columbia
•
Filing: 1994-07-19
•
Granted: —
•
Expires: 2014-07-19
Abstract
Abstract The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
Inventors
- 👤 Helen M. Burt
- 👤 John K. Jackson
- 👤 William L. Hunter
- 👤 Lindsay S. Machan
- 👤 Larry A. Arsenault
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 03:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K33/00; A61K33/24; A61K9/00; A61K9/14; A61K31/12; A61K31/122; A61K31/13; A61K31/135; A61K31/136; A61K31/16; A61K31/165; A61K31/203; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/41; A61K31/425; A61K31/426; A61K31/427; A61K31/435; A61K31/47; A61K31/4738; A61K31/4745; A61K31/495; A61K31/505; A61K31/519; A61K31/525; A61K31/555; A61K31/56; A61K31/565; A61K31/57; A61K31/70; A61K31/702; A61K33/06; A61K33/30; A61K38/00; A61K38/16; A61K38/55; A61K38/57; A61K45/00; A61K45/06; A61K9/0012; A61K9/0019; A61K9/0048; A61K9/0051; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635; A61K9/1641; A61K9/1647; A61K9/1658; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5031; A61K9/51; A61K9/5107; A61K9/513; A61K9/5146; A61K9/5153; A61K9/70; A61K9/7007; A61L; A61L31/00; A61L31/08; A61L31/10; A61L31/14; A61L31/145; A61L31/16; A61P; A61P1/00; A61P1/04; A61P1/16; A61P11/00; A61P13/00; A61P13/02; A61P19/00; A61P19/02; A61P27/00; A61P27/02; A61P35/00; A61P43/00; A61P7/00; A61P7/02; A61P7/04; A61P9/00; A61P9/10; A61P9/14; C; C07; C07C; C07C233/00; C07C233/64; C07K; C07K14/00; C07K14/81; C07K14/8107; C07K14/811; C08; C08L; C08L23/00; C08L23/02; C08L23/04; C08L23/08; C08L23/0846; C08L23/0853; C08L67/00; C08L67/04; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2300/62; A61L2300/622; A61L2430/00; A61L2430/36; B; B82; B82Y; B82Y5/00; C08L2203/00; C08L2203/02; C08L2312/00; C08L29/00; C08L29/02; C08L29/04; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/902; Y10S977/904; Y10S977/915
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
12 words
A composition, comprising: (a) an anti-angiogenic factor; and (b) a polymeric carrier.
Claim 2
Dependent Claim
23 words
The composition according to claim 1 wherein said composition is formed into microspheres having an average size of between 0.5 and 200 µm.
Claim 3
Dependent Claim
24 words
The composition according to claim 1 wherein said composition is formed into a film with a thickness of between 100 µm and 2 mm.
Claim 4
Dependent Claim
19 words
The composition according to claim 1 wherein said composition is liquid above 45°C, and solid or semi-solid at 37°C.
Claim 5
Dependent Claim
15 words
The composition according to claim 1 wherein said polymeric carrier is poly(ethylene-vinyl acetate) (40% crosslinked).
Claim 6
Dependent Claim
18 words
The composition according to claim 1 wherein said polymeric carrier is copolymer of lactic acid and glycolic acid.
Claim 7
Dependent Claim
13 words
The composition according to claim 1 wherein said polymeric carrier is poly (caprolactone).
Claim 8
Dependent Claim
14 words
The composition according to claim 1 wherein said polymeric carrier is poly (lactic acid).
Claim 9
Dependent Claim
20 words
The composition according to claim 1 wherein said polymeric carrier is a copolymer of poly (lactic acid) and poly (caprolatone).
Claim 10
Dependent Claim
33 words
The composition according to claim 1 wherein said anti-angiogenic factor is selected from the group consisting of, suramin, Tissue Inhibitor of Metalloproteinases and retinoic acids, and taxol, or an analog or derivative thereof.
Claim 11
Dependent Claim
23 words
Use of a composition comprising an anti-angiogenic factor and a polymeric carrier, for the manufacture of a medicament for embolizing a blood vessel.
Claim 12
Dependent Claim
12 words
Use according to claim 11 wherein said blood vessel nourishes a tumor.
Claim 13
Dependent Claim
20 words
A stent for expanding the lumen of a body passageway, comprising a generally tubular structure coated with an anti-angiogenic factor.
Claim 14
Dependent Claim
13 words
A stent according to claim 13 wherein said stent is a vascular stent.
Claim 15
Dependent Claim
33 words
A stent according to claim 15, wherein said anti-angiogenic factor is selected from the group consisting of, suramin, Tissue Inhibitor of Metalloproteinases and retinoic acids, and taxol, or an analogue ore derivative thereof.
Claim 16
Dependent Claim
18 words
A stent according to any one of claims 13 to 15 for treating narrowing of a body passageway.
Claim 17
Dependent Claim
7 words
A graft, coated with an anti-angiogenic factor.
Claim 18
Dependent Claim
33 words
A graft according to claim 17 wherein said anti-angiogenic factor is selected from the group consisting of, suramin, Tissue Inhibitor of Metalloproteinases and retinoic acids, and taxol, or an analogue or derivative thereof.
Claim 19
Dependent Claim
15 words
A graft according to any one of claims 17 or 18 for treating neointimal hyperplasia.
Claim 20
Dependent Claim
19 words
Use of a composition comprising an anti-angiogenic factor for the manufacture of a medicament for treating non-tumorigenic angiogenesis-dependent disease.
Claim 21
Dependent Claim
16 words
Use according to claim 20 wherein said angiogenesis-dependent disease is a neovascular disease of the eye.
Claim 22
Dependent Claim
31 words
Use according to claim 20 wherein said angiogenesis-dependent disease is selected from the group consisting of hypertrophic scars and keloids, proliferative diabetic retinopathy, arthritis, arteriovenous malformations, psoriasis, scleroderma and vascular adhesions.
Claim 23
Dependent Claim
32 words
Use according to claim 20 wherein said anti-angiogenic factor is selected from the group consisting of, suramin, Tissue Inhibitor of Metalloproteinases and retinoic acids, and taxol, or an analogue or derivative thereof.
Claim 24
Dependent Claim
13 words
Use according to claim 20 wherein said composition further comprises a polymeric carrier.
Claim 25
Dependent Claim
19 words
Use of a composition comprising an anti-angiogenic factor for the manufacture of a medicament for treating tumor excision sites.
Claim 26
Dependent Claim
32 words
Use according to claim 25 wherein said anti-angiogenic factor is selected from the group consisting of, suramin, Tissue Inhibitor of Metalloproteinases and retinoic acids, and taxol, or an analogue or derivative thereof.
Claim 27
Dependent Claim
13 words
Use according to claim 25 wherein said composition further comprises a polymeric carrier.
References Cited (Backward Citations)
US4776337A
Cited
US4776337B1
Cited
US5041126A
Cited
CA2024306A1
Cited
US5052998A
Cited
US5064435A
Cited
US5147370A
Cited
US5229526A
Cited
US5283253A
Cited
WO1993010076A1
Cited
US5176626A
Cited
US5200534A
Cited
WO1993023555A1
Cited
US5274137A
Cited
US5294637A
Cited
US5202448A
Cited
EP0590267A2
Cited
WO1994007881A1
Cited
WO1994007880A1
Cited
WO1994007876A1
Cited
WO1994007882A1
Cited
US5279949A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.